The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors
- PMID: 21910627
- DOI: 10.1146/annurev-pharmtox-010611-134514
The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors
Abstract
It is now acknowledged that G protein-coupled receptors, the largest class of drug targets, adopt multiple active states that can be preferentially stabilized by orthosteric ligands or allosteric modulators, thus giving rise to the phenomenon of pathway-biased signaling. In the past few years, researchers have begun to explore the potential of linking orthosteric and allosteric pharmacophores to yield bitopic hybrid ligands. This approach is an extension of the more traditional bivalent ligand concept and shares some of the same challenges, including the choice and role of the linker between the two pharmacophores and the validation of mechanism of action. Nonetheless, the promise of bitopic ligands is the generation of novel chemical tools that have improved affinity and/or selectivity profiles. Previously identified functionally selective compounds (and medicines) also may act via a bitopic mechanism, suggesting that the phenomenon is more widespread than currently appreciated.
Similar articles
-
Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.Mol Interv. 2009 Jun;9(3):125-35. doi: 10.1124/mi.9.3.6. Mol Interv. 2009. PMID: 19592673 Review.
-
Bridging the gap: bitopic ligands of G-protein-coupled receptors.Trends Pharmacol Sci. 2013 Jan;34(1):59-66. doi: 10.1016/j.tips.2012.10.003. Epub 2012 Nov 20. Trends Pharmacol Sci. 2013. PMID: 23177916 Review.
-
Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.Angew Chem Int Ed Engl. 2013 Jan 7;52(2):508-16. doi: 10.1002/anie.201205315. Epub 2012 Dec 6. Angew Chem Int Ed Engl. 2013. PMID: 23225228 Review.
-
Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.Neuropharmacology. 2011 Jan;60(1):24-35. doi: 10.1016/j.neuropharm.2010.07.010. Epub 2010 Jul 15. Neuropharmacology. 2011. PMID: 20637785 Review.
-
Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry.J Med Chem. 2017 May 25;60(10):4126-4134. doi: 10.1021/acs.jmedchem.6b01601. Epub 2017 Feb 15. J Med Chem. 2017. PMID: 28140580 Review.
Cited by
-
Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.Eur Neuropsychopharmacol. 2015 Sep;25(9):1448-61. doi: 10.1016/j.euroneuro.2014.11.013. Epub 2014 Nov 29. Eur Neuropsychopharmacol. 2015. PMID: 25583363 Free PMC article.
-
Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand.J Med Chem. 2015 Sep 10;58(17):6819-43. doi: 10.1021/acs.jmedchem.5b00585. Epub 2015 Aug 28. J Med Chem. 2015. PMID: 26258690 Free PMC article.
-
2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.J Med Chem. 2020 Mar 12;63(5):1779-1797. doi: 10.1021/acs.jmedchem.9b01105. Epub 2019 Sep 24. J Med Chem. 2020. PMID: 31499001 Free PMC article.
-
What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?Pharmacol Rev. 2015;67(1):198-213. doi: 10.1124/pr.114.009944. Pharmacol Rev. 2015. PMID: 25527701 Free PMC article. Review.
-
Cannabinoid receptor activation correlates with the proapoptotic action of the β2-adrenergic agonist (R,R')-4-methoxy-1-naphthylfenoterol in HepG2 hepatocarcinoma cells.J Pharmacol Exp Ther. 2012 Oct;343(1):157-66. doi: 10.1124/jpet.112.195206. Epub 2012 Jul 9. J Pharmacol Exp Ther. 2012. PMID: 22776956 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
